Regorafenib: A Novel Multitargeted Tyrosine Kinase Inhibitor for Colorectal Cancer and Gastrointestinal Stromal Tumors

Annals of Pharmacotherapy

Volumn 47, Issue 12, 2013, Pages 1685-1696

  Crona, Daniel J ^a   Keisler, Meredith D ^b   Walko, Christine M ^a,c  

^a University of North Carolina   (United States)

^b UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

colorectal cancer; gastrointestinal stromal tumors; regorafenib

Indexed keywords

IMATINIB; IRINOTECAN; KETOCONAZOLE; PLACEBO; REGORAFENIB; RIFAMPICIN; SUNITINIB;

ALOPECIA; ANOREXIA; BLEEDING; COLORECTAL CANCER; CONSTIPATION; DIARRHEA; DIGESTIVE SYSTEM FISTULA; DIGESTIVE SYSTEM PERFORATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPHONIA; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; HAND FOOT SYNDROME; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; HYPERURICEMIA; HYPOPHOSPHATEMIA; IC 50; LIVER TOXICITY; METASTATIC COLORECTAL CANCER; MONOTHERAPY; MYALGIA; NAUSEA; ORAL MUCOSITIS; OVERALL SURVIVAL; PATIENT COUNSELING; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; REVIEW; SKIN MANIFESTATION; THROMBOEMBOLISM; WOUND HEALING IMPAIRMENT;

COLORECTAL CANCER; GASTROINTESTINAL STROMAL TUMORS; REGORAFENIB;

ANIMALS; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DRUG INTERACTIONS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; PYRIDINES;

EID: 84891671103     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028013509792     Document Type: Review

References (36)

1. Washington, DC: National Institutes of Health, National Cancer Institute;.
2. Siegel R,Ward E,Brawley O,Jemal A.Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths.CA: Cancer J Clin. 2011;61:212-236.
3. Markowitz SD,Bertagnolli MM.Molecular origins of cancer: molecular basis of colorectal cancer.N Engl J Med. 2009;361:2449-2460.
4. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: colon cancer. Version 3.2013. http://www.nccn.org. Accessed March 1, 2013.
5. Miettinen M,Lasota J.Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis.Arch Pathol Lab Med. 2006;130:1466-1478.
6. Pisters PW,Blanke CD,von Mehren Met al.A USA registry of gastrointestinal stromal tumor patients: changes in practice over time and differences between community and academic practices.Ann Oncol. 2011;22:2523-2529.
7. Corless CL,Heinrich MC.Molecular pathobiology of gastrointestinal stromal sarcomas.Annu Rev Pathol. 2008;3:557-586.
8. Dematteo RP,Ballman KV,Antonescu CRet al.Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.Lancet. 2009;373:1097-1104.
9. Blesius A,Cassier PA,Bertucci Fet al.Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial.BMC Cancer. 2011;11:72.
10. Joensuu H,Eriksson M,Sundby Hall Ket al.One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.JAMA. 2012;307:1265-1272.
11. Heinrich MC,Corless CL,Blanke CDet al.Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.J Clin Oncol. 2006;24:4764-4774.
12. Heinrich MC,Maki RG,Corless CLet al.Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.J Clin Oncol. 2008;26:5352-5359.
13. Wilhelm SM,Dumas J,Adnane Let al.Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity.Int J Cancer. 2011;129:245-255.
14. Stivarga (regorafenib) [product information]. Wayne, NJ: Bayer HealthCare Pharmaceuticals, Inc; 2013. http://labeling.bayerhealthcare.com/html/products/pi/Stivarga_PI.pdf. Accessed March 1, 2013.
15. Wilhelm SM,Carter C,Tang Let al.BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.Cancer Res. 2004;64:7099-7109.
16. Mross K,Frost A,Steinbild Set al.A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors.Clin Cancer Res. 2012;18:2658-2667.
17. Strumberg D,Scheulen ME,Schultheis Bet al.Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study.Br J Cancer. 2012;106:1722-1727.
18. Cancer Therapy Evaluation Program, Common Terminology for Adverse Events, version 3.0, DCTD, NCI,NIH, DHHS. March31, 2003. Published August 9, 2006. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf. Accessed March 3, 2013.
19. Grothey A,Van Cutsem E,Sobrero Aet al.Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.Lancet. 2013;381:303-312.
20. Demetri GD,Reichardt P,Kang YKet al.Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.Lancet. 2013;381:295-302.
21. Llovet JM,Ricci S,Mazzaferro Vet al.Sorafenib in advanced hepatocellular carcinoma.N Engl J Med. 2008;359:378-390.
22. Eisenhauer EA,Therasse P,Bogaerts Jet al.New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).Eur J Cancer. 2009;45:228-247.
23. Therasse P,Arbuck SG,Eisenhauer EAet al.New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.J Natl Cancer Inst. 2000;92:205-216.
24. Van Cutsem E,Sobrero A,Siena Set al.Regorafenib (REG) in progressive metastatic colorectal cancer (mCRC): analysis of age subgroups in the phase III CORRECT trial.J Clin Oncol. 2013;31:.
25. George S,Wang Q,Heinrich MCet al.Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial.J Clin Oncol. 2012;30:2401-2407.
26. Cancer Therapy Evaluation Program, Common Terminology for Adverse Events, version 4.0, DCTD, NCI,NIH, DHHS. PublishedMay29, 2009. http://evs.nci.nih.gov/ftp1/CTCAE/Archive/CTCAE_4.0_2009-05-29_QuickReference_5x7.pdf. Accessed March 15, 2013.
27. Grothey A,Sobrero AF,Siena Set al.Time profile of adverse events (AEs) from regorafenib (REG) treatment for metastatic colorectal cancer (mCRC) in the phase III CORRECT study.J Clin Oncol. 2013;31:.
28. Schultheis B,Folprecht G,Kuhlmann Jet al.Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study.Ann Oncol. 2013;24:1560-1567.
29. Lacouture ME,Wu S,Robert Cet al.Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib.Oncologist. 2008;13:1001-1011.
30. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: soft tissue sarcoma. Version 3.2012. http://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf. Accessed March 30, 2013.
31. Schultheis B,Folprecht G,Kuhlmann Jet al.Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study.Ann Oncol. :.
32. Regorafenib+FOLFIRI versus placebo+FOLFIRI as 2nd Line Tx in metastatic colorectal cancer (NCT01298570). http://www.clinicaltrials.gov/ct2/show/NCT01298570?term=NCT01298570&rank=1. Accessed March 28, 2013.
33. First line treatment of metastatic colorectal cancer with mFOLFOX6 in combination with regorafenib (NCT01289821). http://www.clinicaltrials.gov/ct2/results?term=NCT01289821&Search=Search. Accessed April 2, 2013.
34. Kies MS,Blumenschein GR,Christiensen O,Lin T,Tolcher AW.Phase I study of regorafenib (BAY 73-4506), an inhibitor of oncogenic and angiogenic kinases, administered continuously in patients with advanced refractory non-small cell lung cancer (NSCLC).J Clin Oncol. 2010;28:.
35. Shimizu T,Tolcher AW,Patnaik Aet al.Phase I dose-escalation study of continuously administered regorafenib (BAY 73-4506), an inhibitor of oncogenic and angiogenic kinases, in patients with advanced solid tumors.J Clin Oncol. 2010;28:.
36. Pugh RN,Murray-Lyon IM,Dawson JL,Pietroni MC,Williams R.Transection of the oesophagus for bleeding oesophageal varices.Br J Surg. 1973;60:646-649.